
Can you summarise the findings from the BE OPTIMAL study regarding pain and fatigue?
“Absolutely. PsA is characterised by joint and skin inflammation, significantly impacting quality-of-life through pain and fatigue. In the BE OPTIMAL and BE COMPLETE studies, we evaluated bimekizumab. Over 2 years, participants experienced sustained improvements in fatigue, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) subscale [4]. Similarly, pain improvements were consistent across the study duration. Notably, even patients who transitioned from adalimumab to bimekizumab at week 52 maintained these benefits through 2 years.”
“Our analysis from the BE OPTIMAL and BE COMPLETE trials also evaluated the relationship between achieving stringent control of swollen joint count (SJC) and reductions in patient-reported pain and fatigue. The data showed that patients who attained complete resolution of swollen joints (SJC=0) experienced the greatest improvements in pain and fatigue, sustained over 2 years. It is so important to target the full resolution of joint inflammation as a key therapeutic goal.”
The dual inhibition of IL-17A and IL-17F by bimekizumab seems to play a pivotal role. How does this mechanism contribute?
“While IL-17A has been a primary target in PsA, recent evidence suggests IL-17F also drives inflammation and tissue damage. By targeting both cytokines, bimekizumab achieves a broader suppression of inflammation. This dual mechanism likely underpins the consistent and sustained improvements in symptoms like fatigue and pain that we’ve observed in these studies.”
What did the BE OPTIMAL and BE COMPLETE studies reveal about work productivity?
“PsA can significantly impair work productivity, affecting absenteeism, presenteeism, and overall activity levels. Using the Work Productivity and Activity Impairment Questionnaire (WPAI-SHP), we found that bimekizumab demonstrated significant and clinically meaningful improvements across all dimensions of work productivity compared with placebo by week 16 [5]. Importantly, these improvements were sustained over 1 year, and patients who transitioned from placebo to bimekizumab experienced similar benefits.“
Were there any differences in work productivity outcomes between biologic-naïve patients and those with prior TNF inhibitor exposure?
“Interestingly, improvements in work productivity were consistent across both biologic DMARD-naïve and TNF inhibitor-experienced populations. By week 16, biologic-naïve patients treated with bimekizumab showed a 16.7% improvement in overall work impairment compared with 3.0% in the placebo group. For TNF inhibitor-experienced patients, the improvement was 15.6% for bimekizumab versus 3.6% for placebo. These gains continued to increase over the year-long study period, reinforcing the efficacy of bimekizumab across diverse patient populations.”
Beyond clinical trial results, you’ve mentioned the importance of real-world creativity in managing PsA, particularly with off-label combination therapies. Could you elaborate?
“’PsA is a heterogeneous disease, and we sometimes need to think outside the box. For instance, dermatologists may prescribe TNF-alpha inhibitors for severe skin involvement, while rheumatologists might focus on IL-23 or IL-17 inhibitors for joint symptoms. Sometimes we can get around off-label combination therapies by coordinating who-prescribes-what and get even better results. This flexibility allows us to tailor treatment to each patient’s unique needs.”
Do you have any final thoughts on what these updates mean for patients?
“The ability to target both IL-17A and IL-17F with bimekizumab represents a significant advance in PsA management. It addresses not only the physical manifestations of the disease but also the broader impact on patients’ lives, such as fatigue and work productivity, with robust safety data and sustained efficacy over 2 years, and soon 3 years. The data highlights the need for clinicians to prioritise comprehensive disease control, including stringent SJC resolution, when tailoring treatment plans. While I can’t discuss specifics before its presentation at the EULAR 2025, I can tell you the 3-year data looks very positive.”
- McInnes IB, et al. Lancet. 2023 Jan 7;401(10370):25-37.
- Merola JF, et al. Lancet. 2023 Jan 7;401(10370):38-48.
- Coates LC, et al. RMD Open. 2024 Feb 22;10(1):e003855.
- Mease PJ, et al. Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies. Abstract 2368, ACR Convergence 2024, 14–19 November, Washington DC, USA.
- Mease PJ, et al. Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies. Abstract 1415, ACR Convergence 2024, 14–19 November, Washington DC, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« AHA Names 7 Cardiovascular Research Breakthroughs in 2024 Next Article
Meet the Expert: Prof C. Ola Landgren discusses the value of real-world evidence »
« AHA Names 7 Cardiovascular Research Breakthroughs in 2024 Next Article
Meet the Expert: Prof C. Ola Landgren discusses the value of real-world evidence »
Table of Contents: ACR 2024
Featured articles
Registry participation can enhance quality of rheumatology care
Meet the Trialist: Prof. Philip J. Mease on the bimekizumab clinical trial program in psoriatic arthritis
Rheumatoid Arthritis
T2T approach in women with RA associated with increased fertility
Positive results for vagus nerve stimulation in RA
Machine learning to aid evaluation of ANA pattern and titer
Systemic Lupus Erythematosus
ACR presents new 2024 Guideline for lupus nephritis
Dapirolizumab pegol associated with less SLE activity and corticosteroid use
Allogeneic CD19-targeting CAR NK-cell therapy for SLE
Osteoarthritis and Osteoporosis
XG005 relieves knee osteoarthritis symptoms in phase 2b study
NT-3 inhibitor relieves pain caused by osteoarthritis
Therapeutic equivalence between denosumab and biosimilar Bmab-1000
Psoriatic Arthritis
Post-hoc analysis of 3 large trials maps sex differences in PsA
Global recruitment associated with higher placebo responses in PsA trials
Gout
Prolonged plasma urate-lowering with a novel pegylated uricase
SGLT2 inhibitor therapy could be beneficial for gout patients
Vasculitis
Fully tapering glucocorticosteroids may be a viable option for GPA
Favourable benefit-risk profile of upadacitinib in giant cell arteritis
Mycophenolate mofetil plus methotrexate is effective in Takayasu’s arteritis
Miscellaneous
Emapalumab rapidly controls MAS in patients with Still’s disease
FcRn blocker nipocalimab improves disease activity in Sjögren’s disease
Inebilizumab associated with reduced flare risk in IgG4-related disease
General Rheumatology
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Related Articles

February 4, 2020
Depression closely related to fatigue in SLE patients
December 2, 2021
Paediatric dermatology in Tunisia: common diagnoses
January 13, 2025
Anifrolumab may delay organ damage in SLE
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com